They named drug discovery and the emerging 'techbio' sector as areas of interest.
COVID-19 fueled huge interest in health-tech startups, with VCs pouring a record $25.1 billion into health and biotech startups in 2021.
Startups in the space are bringing new applications of tech to fields such as drug discovery, bioengineering, and patient care.
VCs are still betting on drug discoveryEven though funding into drug discovery startups has significantly stalled this year, at just $126 million, startup valuations have picked up since 2022.
Health-tech VCs won't splurge cashWhile COVID-19 did give healthtech startups a chance at the spotlight, they were still overshadowed by their counterparts in fintech and software-as-a-service.
Persons:
techbio, healthtech
Organizations:
Morning, VCs, pharma, Big Pharma
Locations:
fintech, Munich, Germany, Europe